EMBC Embecta Corp. logo

EMBC Embecta Corp.

Healthcare
$3.33+0.00%OpenMarket Cap: $197.3M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

3.76

PEG

0.03

P/B

-0.31

P/S

0.19

EV/EBITDA

4.11

DCF Value

$39.73

FCF Yield

103.9%

Div Yield

18.1%

Margins & Returns

Gross Margin

62.5%

Operating Margin

29.8%

Net Margin

10.7%

ROE

-17.5%

ROA

10.9%

ROIC

25.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 null$221.8M$-4.1M$
Q1 null$261.2M$44.1M$
Q4 null$264.0M$26.4M$
FY null$1.08B$95.4M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

0 Strong Buy1 Buy3 Hold0 Sell1 Strong Sell
B of A SecuritiesUnderperform
2026-05-18
MizuhoNeutral
2026-05-06
BTIGNeutral
2026-05-06
BTIGBuy
2026-02-06
BTIGBuy
2025-09-05

Trading Activity

Insider Trades

View All
Reidy Christopher Rdirector
SellFri Feb 13
Prange Karendirector
SellFri Feb 13
Pomeroy Clairedirector
SellFri Feb 13
Morris Milton Mayodirector
SellFri Feb 13
HOMBACH ROBERT J.director
SellFri Feb 13

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

1.05

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Peers